Low
₹
High
₹
| Previous Close | ₹260.90 |
|---|---|
| Day's Range | ₹260.90 - ₹271.00 |
| Open | ₹268.00 |
| 52 Week Range | ₹229.95 - ₹328.00 |
| Volume | 39,000 |
| Market Cap | ₹0.00 |
| Trade Value ( ₹ in Lacs) | 101.75 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 16.29 |
| TTM EPS (₹) | 15.96 |
| P/E Ratio | 25.16 |
| Book Value(₹) | 3.34 |
| PAT Margin (%) | 12.07 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 19.17 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 869.65 | 165.09 |
| Expenses | N/A | N/A |
| PBT | 136.15 | 39.48 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 104.95 | 30.28 |
| Founded | 2014 |
|---|---|
| Managing Director | Shravan Harikrishna Patel |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,52,982.45 | 1,938.85 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,361.19 | 6,815.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,64,736.63 | 4,896.65 | 3,307.60 - 3,307.60 |
| Apollo Hospitals Enterprise Ltd. | 1,25,808.70 | 8,837.50 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,655.17 | 1,441.70 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,14,613.19 | 1,159.85 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,12,572.73 | 1,269.80 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,12,362.61 | 2,504.75 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,05,561.24 | 1,097.30 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,02,794.70 | 2,541.55 | 1,909.70 - 1,909.70 |
No Records Found
Pursuant to the provisions of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, Hikal has informed that it enclosed confirmation certificate dated July 01, 2026, received from MUFG Intime India, Registrar and Share Transfer Agent (RTA) of the Company, for the quarter ended June 30, 2026.
The above information is a part of company’s filings submitted to BSE.
HealthCare Global Enterprises has informed that, pursuant to provisions of Section 110 of the Companies Act, 2013, read with Rule 22 of the Companies (Management and Administration) Rules, 2014, Regulation 44(3) of SEBI Listing Regulations, and further to its intimation to Stock Exchanges on June 08, 2026, the approval of members of the Company was sought by remote e-voting process in respect of the resolutions set out in the Postal Ballot Notice dated June 08, 2026. In this regard, it enclosed the following: (i) Voting Results in compliance with Regulation 44(3) of SEBI Listing Regulations; and (ii) Consolidated Report of the Scrutinizer dated July 09, 2026, issued by, V Sreedharan, Senior Partner, V Sreedharan and Associates, Company Secretaries, on the remote e-voting conducted through the Postal Ballot process, pursuant to the provisions of Section 110 of the Companies Act, 2013 read with Rule 22 of the Companies (Management and Administration) Rules, 2014. Detailed information in this regard in accordance with Regulation 30 read with SEBI Circulars SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated January 30, 2026, is annexed as Annexure-A. The above information is also available on the website of the Company and can be accessed at: https://www.hcgoncology.com/.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Trident Lifeline Ltd. is ₹260.90 as of 2026-07-09.
The market capitalisation of Trident Lifeline Ltd. is ₹310.26 as of 2026-07-08.
The 1-year return of Trident Lifeline Ltd. is -4.30% as of 2025-07-08.
The P/E ratio of Trident Lifeline Ltd. is 25.16 as of 2026-07-09.
The 52-week high and low of Trident Lifeline Ltd. are ₹328.00 and ₹229.95, respectively, as of 2026-07-09.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.